Money
Shifts in Global Pharma Landscape: Trump and China Impact Europe
The pharmaceutical industry in Europe faces challenges as companies point to fragmented capital markets and inconsistent policies, compounded by external pressures from U.S. and Chinese developments.
editorial-staff
1 min read
Updated about 19 hours ago
Summary
The European pharmaceutical sector is reportedly under strain as companies highlight issues such as fragmented capital markets and inconsistent reimbursement policies.
Recent developments, including U.S. policy shifts and China's growing biotech industry, are contributing to a challenging environment for Europe's pharma companies.
Concerns about pricing and clinical trial regulations within the single market further complicate the landscape, raising questions about the future of Europe's position in global pharmaceuticals.
Updates
- No subsequent updates recorded.